BG Medicine, Inc. (BGMD)
OTCMKTS
· Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
Jan 21, 2025, 4:00 PM EST
BG Medicine Statistics
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
BG Medicine has 11.37 million shares outstanding.
| Current Share Class | n/a |
| Shares Outstanding | 11.37M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +14.20% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.00 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.65
| Current Ratio | 1.65 |
| Quick Ratio | 1.45 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -28.13 |
Financial Efficiency
Return on equity (ROE) is -902.64% and return on invested capital (ROIC) is -135.22%.
| Return on Equity (ROE) | -902.64% |
| Return on Assets (ROA) | -75.95% |
| Return on Capital (ROIC) | -135.22% |
| Revenue Per Employee | 313,200 |
| Profits Per Employee | -1.39M |
| Employee Count | 5 |
| Asset Turnover | 0.43 |
| Inventory Turnover | 1.85 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | 77.81 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 46.30 |
| Average Volume (20 Days) | 14,785 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.00 |
Income Statement
In the last 12 months, BG Medicine had revenue of 1.57 million and -6.96 million in losses. Loss per share was -0.72.
| Revenue | 1.57M |
| Gross Profit | 1.06M |
| Operating Income | -4.47M |
| Pretax Income | -5.30M |
| Net Income | -6.96M |
| EBITDA | -4.39M |
| EBIT | -4.47M |
| Loss Per Share | -0.72 |
Balance Sheet
| Cash & Cash Equivalents | 1.53M |
| Total Debt | n/a |
| Net Cash | 1.53M |
| Net Cash Per Share | 0.13 |
| Equity (Book Value) | 618,000 |
| Book Value Per Share | -0.17 |
| Working Capital | 771,000 |
Cash Flow
| Operating Cash Flow | -3.67M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 67.75% |
| Operating Margin | -285.63% |
| Pretax Margin | -338.63% |
| Profit Margin | n/a |
| EBITDA Margin | -280.08% |
| EBIT Margin | -285.63% |
| FCF Margin | n/a |
Dividends & Yields
BG Medicine does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -17.53% |
| Shareholder Yield | -17.53% |
| Earnings Yield | -72,408,200.00% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on July 9, 2015. It was a reverse split with a ratio of 0.25.
| Last Split Date | Jul 9, 2015 |
| Split Type | Reverse |
| Split Ratio | 0.25 |
Scores
BG Medicine has an Altman Z-Score of -108.34. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -108.34 |
| Piotroski F-Score | n/a |